BLASOLUTIONINJECTION
Approved
Jul 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
EPYSQLI (eculizumab-aagh) by Samsung Bioepis is complement inhibitors [moa]. First approved in 2024.
Drug data last refreshed 2d ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EPYSQLI (eculizumab-aagh) is a monoclonal antibody complement inhibitor approved by the FDA on July 19, 2024, as a biosimilar to the reference eculizumab product. It blocks complement component C5, preventing terminal complement activation and hemolysis in rare blood disorders and other complement-mediated conditions.
Growth
Early-stage growth phase for a newly approved biosimilar positions the brand team to establish market presence against an entrenched reference product with moderate competitive pressure (30/100).
Mechanism of Action
Complement Inhibitors
Pharmacologic Class:
Complement Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on EPYSQLI offers exposure to biosimilar launch strategy, payer negotiations, and competing against an entrenched reference product in a niche rare disease market. Teams are typically smaller and leaner than originator brands, requiring adaptability and deep health economics expertise.
Brand ManagerField Sales Representative
Worked on EPYSQLI at Samsung Bioepis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.